AUG 18, 2026 · JOURNAL ARTICLE
A multicohort, biomarker-driven phase 2 trial of personalized total neoadjuvant therapy with targeted agents for high-risk rectal cancer (The TRAINER study)
Signal Transduction and Targeted Therapy
A single-center phase 2 trial with a meaningful primary endpoint (40% complete response) and acceptable safety, but limited by lack of control group, modest sample size, and single-center design requiring confirmation in larger studies.
Reported
Primary endpoint (complete respon…40% (36/90)
Complete response in cohort B18 patients
Complete response in cohort C18 patients